The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives

References

• Choi MY, Fritzler MJ. Autoantibodies in SLE: prediction and the p value matrix. Lupus. 2019;28(11):1285–1293. doi:10.1177/0961203319868531
   PubMed Web of Science ®Google Scholar
• Sebastiani GD, Prevete I, Piga M, et al. Early Lupus Project - A multicentre Italian study on systemic lupus erythematosus of recent onset. Lupus. 2015;24(12):1276–1282. doi:10.1177/0961203315585817
   PubMed Web of Science ®Google Scholar
• Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010;19(8):949–956. doi:10.1177/0961203310366572
   PubMed Web of Science ®Google Scholar
• Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev. 2009;8(4):337–342. doi:10.1016/j.autrev.2008.12.008
   PubMed Web of Science ®Google Scholar
• Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis. 2011;70(9):1569–1574. doi:10.1136/ard.2010.148494
   PubMed Web of Science ®Google Scholar
• Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus sci med. 2019;6(1):e000336. doi:10.1136/lupus-2019-000336
   PubMed Web of Science ®Google Scholar
• Guerra SG, Vyse TJ, Cunninghame graham DS. The genetics of lupus: a functional perspective. Arthritis Res Ther. 2012;14(3):211. doi:10.1186/ar3844
   PubMed Web of Science ®Google Scholar
• Dai C, Deng Y, Quinlan A, Gaskin F, Tsao BP, Fu SM. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol. 2014;31:87–96. doi:10.1016/j.coi.2014.10.004
   PubMed Web of Science ®Google Scholar
• Harley JB, Alarcón-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40(2):204–210. doi:10.1038/ng.81
   PubMed Web of Science ®Google Scholar
• Demirci FY, Wang X, Morris DL, et al. Multiple signals at the extended 8p23 locus are associated with susceptibility to systemic lupus erythematosus. J Med Genet. 2017;54(6):381–389. doi:10.1136/jmedgenet-2016-104247
   PubMed Web of Science ®Google Scholar
• Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008;358(9):900–909. doi:10.1056/NEJMoa0707865
   PubMed Web of Science ®Google Scholar
• Guthridge JM, Lu R, Sun H, et al. Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet. 2014;94(4):586–598. doi:10.1016/j.ajhg.2014.03.008
   PubMed Web of Science ®Google Scholar
• Raj P, Song R, Zhu H, et al. Deep sequencing reveals a DAP1 regulatory haplotype that potentiates autoimmunity in systemic lupus erythematosus. Genome Biol. 2020;21(1):281. doi:10.1186/s13059-020-02184-z
   PubMed Web of Science ®Google Scholar
• Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; the tart cell and the L.E. cell. Proc Staff Meet Mayo Clin. 1948;23(2):25–28.
   PubMed Web of Science ®Google Scholar
• Holborow EJ, Weir DM, Johnson GD. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br Med J. 1957;2(5047):732–734. doi:10.1136/bmj.2.5047.732
   PubMed Web of Science ®Google Scholar
• Robbins WC, Holman HR, Deicher H, Kunkel HG. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proce Soc Exp Biol Med Soc Exp Biol Med. 1957;96(3):575–579. doi:10.3181/00379727-96-23545
   PubMed Web of Science ®Google Scholar
• Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med. 1996;156(13):1421–1425. doi:10.1001/archinte.1996.00440120079007
   PubMedGoogle Scholar
• Abeles AM, Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med. 2013;126(4):342–348. doi:10.1016/j.amjmed.2012.09.014
   PubMed Web of Science ®Google Scholar
• Heremans H, Billiau A, Colombatti A, Hilgers J, de Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun. 1978;21(3):925–930. doi:10.1128/iai.21.3.925-930.1978
   PubMed Web of Science ®Google Scholar
• Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227(3):207–210. doi:10.1111/j.1365-2796.1990.tb00144.x
   PubMed Web of Science ®Google Scholar
• Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002;32(3):163–173. doi:10.1053/sarh.2002.37277
   PubMed Web of Science ®Google Scholar
• Fujibayashi T, Hooks JJ, Notkins AL. Production of interferon by immune lymphocytes exposed to herpes simplex virus-antibody complexes. J Immunol. 1975;115(5):1191–1193.
   PubMed Web of Science ®Google Scholar
• Green NM, Marshak-Rothstein A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol. 2011;23(2):106–112. doi:10.1016/j.smim.2011.01.016
   PubMed Web of Science ®Google Scholar
• Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol. 1999;115(1):196–202. doi:10.1046/j.1365-2249.1999.00772.x
   PubMed Web of Science ®Google Scholar
• Vallin H, Perers A, Alm GV, Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol. 1999;163(11):6306–6313.
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294(5546):1540–1543. doi:10.1126/science.1064890
   PubMed Web of Science ®Google Scholar
• Le Bon A, Thompson C, Kamphuis E, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol. 2006;176(4):2074–2078. doi:10.4049/jimmunol.176.4.2074
   PubMed Web of Science ®Google Scholar
• Lambers WM, Westra J, Bootsma H, de Leeuw K. From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. Semin Arthritis Rheum. 2021;51(1):43–48. doi:10.1016/j.semarthrit.2020.11.006
   PubMed Web of Science ®Google Scholar
• Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999;17(5):615–620.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum. 1980;23(3):341–343. doi:10.1002/art.1780230312
   PubMed Web of Science ®Google Scholar
• Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum. 1991;21(1):55–64. doi:10.1016/0049-0172(91)90057-7
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus erythematosus–survival patterns. Experience with 609 patients. JAMA. 1981;245(9):934–938. doi:10.1001/jama.1981.03310340024021
   PubMed Web of Science ®Google Scholar
• Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119(8):700–706. doi:10.1016/j.amjmed.2005.11.034
   PubMed Web of Science ®Google Scholar
• Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology. 2004;43(12):1580–1586. doi:10.1093/rheumatology/keh392
   PubMed Web of Science ®Google Scholar
• Wijeyesinghe U, Russell AS. Outcome of high titer antinuclear antibody positivity in individuals without connective tissue disease: a 10-year follow-up. Clin Rheumatol. 2008;27(11):1399–1402. doi:10.1007/s10067-008-0932-y
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–1533. doi:10.1056/NEJMoa021933
   PubMed Web of Science ®Google Scholar
• Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. doi:10.1186/ar3258
   PubMed Web of Science ®Google Scholar
• McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005;11(1):85–89. doi:10.1038/nm1167
   PubMed Web of Science ®Google Scholar
• Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012;2012:606195. doi:10.1155/2012/606195
   PubMedGoogle Scholar
• Calvo-Alen J, Alarcon GS, Burgard SL, Burst N, Bartolucci AA, Williams HJ. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol. 1996;23(3):469–475.
   PubMed Web of Science ®Google Scholar
• Al Daabil M, Massarotti EM, Fine A, et al. Development of SLE among “potential SLE” patients seen in consultation: long-term follow-up. Int J Clin Pract. 2014;68(12):1508–1513. doi:10.1111/ijcp.12466
   PubMed Web of Science ®Google Scholar
• Vilá LM, Mayor AM, Valentín AH, García-Soberal M, Vilá S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000;9(2):110–115. doi:10.1191/096120300678828073
   PubMed Web of Science ®Google Scholar
• Ståhl Hallengren C, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus. 2004;13(2):85–88. doi:10.1191/0961203304lu477oa
   PubMed Web of Science ®Google Scholar
• Swaak AJ, van de Brink H, Smeenk RJ, et al. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology. 2001;40(1):89–94. doi:10.1093/rheumatology/40.1.89
   PubMed Web of Science ®Google Scholar
• Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern Med. 1989;149(11):2473–2476. doi:10.1001/archinte.1989.00390110061013
   PubMedGoogle Scholar
• Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012;14(4):R174. doi:10.1186/ar3927
   PubMed Web of Science ®Google Scholar
• Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48:50–52. doi:10.1016/j.jaut.2014.01.019
   PubMed Web of Science ®Google Scholar
• Ganczarczyk L, Urowitz MB, Gladman DD. Latent lupus. J Rheumatol. 1989;16(4):475–478.
   PubMed Web of Science ®Google Scholar
• Aberle T, Bourn RL, Chen H, et al. Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus sci med. 2017;4(1):e000176. doi:10.1136/lupus-2016-000176
   PubMed Web of Science ®Google Scholar
• Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066–1073. doi:10.1172/JCI38010
   PubMed Web of Science ®Google Scholar
• Lenert A, Niewold TB, Lenert P. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2017;11:747–757. doi:10.2147/DDDT.S114552
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi:10.1002/art.30613
   PubMed Web of Science ®Google Scholar
• Slight-Webb S, Smith M, Bylinska A, et al. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020;146(6):1419–1433. doi:10.1016/j.jaci.2020.04.047
   PubMed Web of Science ®Google Scholar
• Munroe ME, Young KA, Kamen DL, et al. Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis rheumatol. 2017;69(3):630–642. doi:10.1002/art.40004
   PubMed Web of Science ®Google Scholar
• Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301(1):5–8. doi:10.1056/NEJM197907053010102
   PubMed Web of Science ®Google Scholar
• Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8(6):492–502. doi:10.1038/sj.gene.6364408
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–2615. doi:10.1073/pnas.0337679100
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–723. doi:10.1084/jem.20021553
   PubMed Web of Science ®Google Scholar
• Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36(8):481–490. doi:10.1080/08916930310001625952
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004;50(12):3958–3967. doi:10.1002/art.20798
   PubMed Web of Science ®Google Scholar
• Li QZ, Zhou J, Lian Y, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol. 2010;159(3):281–291. doi:10.1111/j.1365-2249.2009.04057.x
   PubMed Web of Science ®Google Scholar
• Lu R, Munroe ME, Guthridge JM, et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016;74:182–193. doi:10.1016/j.jaut.2016.06.001
   PubMed Web of Science ®Google Scholar
• Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987;70(3):562–569.
   PubMed Web of Science ®Google Scholar
• Munroe ME, Lu R, Zhao YD, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014–2021. doi:10.1136/annrheumdis-2015-208140
   PubMed Web of Science ®Google Scholar
• Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008;58(8):2481–2487. doi:10.1002/art.23613
   PubMed Web of Science ®Google Scholar
• Salloum R, Franek BS, Kariuki SN, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010;62(2):553–561. doi:10.1002/art.27182
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018;77(10):1432–1439. doi:10.1136/annrheumdis-2018-213386
   PubMed Web of Science ®Google Scholar
• Lambers WM, De leeuw K. Doornbos-van der Meer B, Diercks GFH, Bootsma H, Westra J. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. Arthritis Res Ther. 2019;21(1):260. doi:10.1186/s13075-019-2034-4
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Imgruet M, Dorschner JM, et al. Novel genetic associations with interferon in systemic lupus erythematosus identified by replication and fine-mapping of trait-stratified genome-wide screen. Cytokine. 2020;132:154631. doi:10.1016/j.cyto.2018.12.014
   PubMed Web of Science ®Google Scholar
• Der E, Suryawanshi H, Morozov P, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019;20(7):915–927. doi:10.1038/s41590-019-0386-1
   PubMed Web of Science ®Google Scholar
• Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis rheumatol. 2008;58(4):1136–1145. doi:10.1002/art.23404
   PubMed Web of Science ®Google Scholar
• Rose T, Grützkau A, Klotsche J, et al. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology. 2017;56(9):1618–1626. doi:10.1093/rheumatology/kex220
   PubMed Web of Science ®Google Scholar
• Oliveira JJ, Karrar S, Rainbow DB, et al. The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):152. doi:10.1186/s13075-018-1649-1
   PubMed Web of Science ®Google Scholar
• Datta SK. Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells. Lupus. 1998;7(9):591–596. doi:10.1191/096120398678920703
   PubMed Web of Science ®Google Scholar
• Kil LP, Hendriks RW. Aberrant B cell selection and activation in systemic lupus erythematosus. Int Rev Immunol. 2013;32(4):445–470.
   PubMed Web of Science ®Google Scholar
• Munroe ME, James JA. Genetics of Lupus Nephritis: clinical Implications. Semin Nephrol. 2015;35(5):396–409. doi:10.1016/j.semnephrol.2015.08.002
   PubMed Web of Science ®Google Scholar
• Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis rheumatol. 2014;66(7):1888–1899. doi:10.1002/art.38573
   PubMed Web of Science ®Google Scholar
• Henning S, Lambers WM. Doornbos-van der Meer B, et al. Proportions of B-cell subsets are altered in incomplete systemic lupus erythematosus and correlate with interferon score and IgG levels. Rheumatology. 2020;59(9):2616–2624. doi:10.1093/rheumatology/keaa114
   PubMed Web of Science ®Google Scholar
• Toro-Domínguez D, Martorell-Marugán J, Goldman D, Petri M, Carmona-Sáez P, Alarcón-Riquelme ME. Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression. Arthritis rheumatol. 2018;70(12):2025–2035. doi:10.1002/art.40653
   PubMed Web of Science ®Google Scholar
• Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis rheumatol. 2020;72(1):78–88. doi:10.1002/art.41093
   PubMed Web of Science ®Google Scholar
• Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology. 2020;59(Suppl5):v4–v11. doi:10.1093/rheumatology/keaa379
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–1277. doi:10.1002/art.1780251101
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686. doi:10.1002/art.34473
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159. doi:10.1136/annrheumdis-2018-214819
   PubMed Web of Science ®Google Scholar
• Olsen NJ, James JA, Arriens C, et al. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018;19(1):694. doi:10.1186/s13063-018-3076-7
   PubMed Web of Science ®Google Scholar
• James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16(6):401–409. doi:10.1177/0961203307078579
   PubMed Web of Science ®Google Scholar
• Lambers WM, Westra J, Bootsma H, de Leeuw K. Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus. J Rheumatol. 2021;48(6):847–851. doi:10.3899/jrheum.200726
   PubMed Web of Science ®Google Scholar
• Olsen NJ, McAloose C, Carter J, et al. Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment. Autoimmune Dis. 2016;2016:8791629. doi:10.1155/2016/8791629
   PubMedGoogle Scholar
• Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R155. doi:10.1186/ar3895
   PubMed Web of Science ®Google Scholar
• Singh N, Kumar B, Aluri V, Lenert P. Interfering with baffled B cells at the lupus tollway: promises, successes, and failed expectations. J Allergy Clin Immunol. 2016;137(5):1325–1333. doi:10.1016/j.jaci.2015.12.1326
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202. doi:10.1136/annrheumdis-2014-206090
   PubMed Web of Science ®Google Scholar
• McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a Phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64(11):3666–3676. doi:10.1002/art.34632
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70(11):1905–1913. doi:10.1136/ard.2010.144485
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a Phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65(4):1011–1021. doi:10.1002/art.37824
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum. 2013;65(2):447–456. doi:10.1002/art.37785
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211–221. doi:10.1056/NEJMoa1912196
   PubMed Web of Science ®Google Scholar